Q3 2014 13F Holders as of 9/30/2014
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
185
-
Total 13F shares, excl. options
-
26.7M
-
Shares change
-
+1.32M
-
Total reported value, excl. options
-
$6.37B
-
Value change
-
+$471M
-
Put/Call ratio
-
0.99
-
Number of buys
-
109
-
Number of sells
-
-85
-
Price
-
$238.57
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q3 2014
222 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q3 2014.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 185 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.7M shares
of 49.6M outstanding shares and own 53.76% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP LLC (5.69M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.54M shares), FMR LLC (2.79M shares), Capital Research Global Investors (1.84M shares), VANGUARD GROUP INC (1.5M shares), BlackRock Institutional Trust Company, N.A. (553K shares), BlackRock Fund Advisors (537K shares), WELLS FARGO & COMPANY/MN (531K shares), FRANKLIN RESOURCES INC (523K shares), and LORD, ABBETT & CO. LLC (512K shares).
This table shows the top 185 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.